# Evaluation of AL3818 in Combination With Nivolumab in Solid Tumors

> **NCT04165330** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Sarcoma Oncology Research Center, LLC** · enrollment: 56 (estimated)

## Conditions studied

- Solid Tumor, Adult
- Soft Tissue Sarcoma
- Non Small Cell Lung Cancer
- Small Cell Lung Cancer

## Interventions

- **DRUG:** AL3818
- **DRUG:** Nivolumab Injection

## Key facts

- **NCT ID:** NCT04165330
- **Lead sponsor:** Sarcoma Oncology Research Center, LLC
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-10-17
- **Primary completion:** 2027-12-31
- **Final completion:** 2028-03-31
- **Target enrollment:** 56 (ESTIMATED)
- **Last updated:** 2025-02-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04165330

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04165330, "Evaluation of AL3818 in Combination With Nivolumab in Solid Tumors". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04165330. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*